Takeda Oncology President Files Form 144 Notice to Sell $940K in ADSs

Transaction Overview

On October 30, 2026, Teresa Bitetti, President of the Global Oncology Business Unit at Takeda Pharmaceutical Company Limited, filed a Form 144 notice disclosing an intention to sell 46,609 American Depositary Shares (ADSs) through Interactive Brokers LLC with an approximate sale date of November 1, 2026. The aggregate market value of the shares is reported as $940,103.53, reflecting an estimated price of approximately $20.17 per ADS.

Origin of Securities & Past Activity

• Acquisition: The 46,609 ADSs were originally acquired on July 30, 2024, through the vesting of Restricted Stock Unit (RSU) awards granted as compensation.
• Prior Sales: In the past three months, Bitetti sold 50,012 ADSs on August 10, 2026, for gross proceeds of $855,205.20. Footnotes indicate that the August sale was executed specifically to satisfy tax withholding obligations related to share vesting effective July 13, 2026.

Market Impact & Significance

• Volume: The 46,609 ADSs represent a negligible fraction (less than 0.03%) of Takeda's 198,318,946 outstanding ADSs.
• Significance: Evaluated as Low. The transaction aligns with standard post-vesting equity monetization and tax planning common among corporate executives, with minimal expected market disruption.